296 related articles for article (PubMed ID: 37196459)
1. Erythrocyte-cancer hybrid membrane-coated reduction-sensitive nanoparticles for enhancing chemotherapy efficacy in breast cancer.
Rezaei S; de Araújo Júnior RF; da Silva ILG; Schomann T; Eich C; Cruz LJ
Biomater Adv; 2023 Aug; 151():213456. PubMed ID: 37196459
[TBL] [Abstract][Full Text] [Related]
2. Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma.
Wang D; Dong H; Li M; Cao Y; Yang F; Zhang K; Dai W; Wang C; Zhang X
ACS Nano; 2018 Jun; 12(6):5241-5252. PubMed ID: 29800517
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy.
Gong C; Yu X; You B; Wu Y; Wang R; Han L; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2020 Jun; 18(1):92. PubMed ID: 32546174
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors.
Jiang Q; Liu Y; Guo R; Yao X; Sung S; Pang Z; Yang W
Biomaterials; 2019 Feb; 192():292-308. PubMed ID: 30465973
[TBL] [Abstract][Full Text] [Related]
5. Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment.
Marshall SK; Angsantikul P; Pang Z; Nasongkla N; Hussen RSD; Thamphiwatana SD
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235009
[TBL] [Abstract][Full Text] [Related]
6. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
7. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
10. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.
Chen WL; Yang SD; Li F; Qu CX; Liu Y; Wang Y; Wang DD; Zhang XN
Acta Biomater; 2018 Nov; 81():219-230. PubMed ID: 30267887
[TBL] [Abstract][Full Text] [Related]
11. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
12. Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system.
Akbarzadeh M; Babaei M; Abnous K; Taghdisi SM; Peivandi MT; Ramezani M; Alibolandi M
Int J Pharm; 2019 Oct; 570():118645. PubMed ID: 31465835
[TBL] [Abstract][Full Text] [Related]
13. A RBC membrane-camouflaged biomimetic nanoplatform for enhanced chemo-photothermal therapy of cervical cancer.
Luo L; Zeng F; Xie J; Fan J; Xiao S; Wang Z; Xie H; Liu B
J Mater Chem B; 2020 May; 8(18):4080-4092. PubMed ID: 32239064
[TBL] [Abstract][Full Text] [Related]
14. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
15. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
16. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.
Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY
J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773
[TBL] [Abstract][Full Text] [Related]
17. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
18. Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species.
Deng L; Feng Z; Deng H; Jiang Y; Song K; Shi Y; Liu S; Zhang J; Bai S; Qin Z; Dong A
ACS Appl Mater Interfaces; 2019 Sep; 11(35):31743-31754. PubMed ID: 31389686
[TBL] [Abstract][Full Text] [Related]
19. A Combinational Approach Towards Treatment of Breast Cancer: an Analysis of Noscapine-Loaded Polymeric Nanoparticles and Doxorubicin.
Esnaashari SS; Muhammadnejad S; Amanpour S; Amani A
AAPS PharmSciTech; 2020 Jun; 21(5):166. PubMed ID: 32504144
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the Effect of Breast Cancer Patients' Plasma on the Targeting Ability of Folic Acid-Modified Chitosan Nanoparticles.
Nemati M; Bani F; Sepasi T; Zamiri RE; Rasmi Y; Kahroba H; Rahbarghazi R; Sadeghi MR; Wang Y; Zarebkohan A; Gao H
Mol Pharm; 2021 Dec; 18(12):4341-4353. PubMed ID: 34779630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
